Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 8/20 | 0.83 |
| ▸ | IGF1R | P08069 | 9/20 | 0.72 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.72 |
| ▸ | INSR | P06213 | 7/20 | 0.72 |
| ▸ | TTK | P33981 | 2/20 | 0.72 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | ROS1 | P08922 | 2/20 | 0.59 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | STK10 | O94804 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | CD74 | P04233 | 1/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919333 | 0.92 | PTK2 (0.79) | PTK2IGF1RALKINSRTTK | |
| SCHEMBL15222130 | 0.92 | PTK2 (0.79) | PTK2IGF1RALKINSRTTK | |
| SCHEMBL11919325 | 0.91 | PTK2 (0.84) | PTK2IGF1RALKINSRMAP4K1 | |
| SCHEMBL11919345 | 0.90 | PTK2 (0.77) | PTK2IGF1RALKINSRMAP4K1 | |
| SCHEMBL11919218 | 0.90 | PTK2 (0.81) | PTK2IGF1RALKINSRTTK | |
| SCHEMBL11918997 | 0.89 | IGF1R (0.82) | PTK2IGF1RALKINSR | |
| SCHEMBL16998990 | 0.89 | PTK2 (0.80) | PTK2IGF1RALKINSRMAP4K1 | |
| SCHEMBL17410930 | 0.88 | PTK2 (0.78) | PTK2IGF1RALKINSRMAP4K1 | |
| SCHEMBL11916477 | 0.84 | ALK (1.00) | PTK2IGF1RALKINSRAURKA | |
| SCHEMBL17731666 | 0.84 | TTK (1.00) | PTK2IGF1RALKINSRTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | claimed |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140024620-A1 | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | PTK2 141/4885IGF1R 543/4885ALK 316/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | PTK2 87/4885IGF1R 526/4885ALK 256/4885 |
| US-20140024620-A1 | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, ERBB2, MKI67 | PTK2 147/4885IGF1R 37/4885ALK 28/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | PTK2 75/4885IGF1R 586/4885ALK 265/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | PTK2 134/4885IGF1R 477/4885ALK 370/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | PTK2 87/4885IGF1R 526/4885ALK 256/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | PTK2 141/4885IGF1R 543/4885ALK 316/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | PTK2 141/4885IGF1R 543/4885ALK 316/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | PTK2 87/4885IGF1R 526/4885ALK 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.